Navigation Links
What is the effect of fluoxetine on mast cell?
Date:12/23/2008

Mast cells are now recognized as "granular cells of the connective tissue", whose activation exacerbates allergic immune responses and as key players in the establishment of innate immunity as well as modulators of adaptive immune responses. The role of mast cells in the gastrointestinal mucosa is not only to react to antigens, but also to actively regulate the barrier and transport properties of the intestinal epithelium. In clinical studies, it has become clear that psychological factors, especially anxiety and depression, play an important role in gastrointestinal diseases by precipitating exacerbation of symptoms. Fluoxetine hydrochloride (fluoxetine) is a kind of selective serotonin reuptake inhibitors (SSRIs), which belong to a class of antidepressants used in the treatment of depression and anxiety disorders.

The research team led by He-Shen Luo, from the Renmin Hospital of Wuhan University of China, investigated the effects of fluoxetine on mast cell morphology and rMCP-1 expression in gastric antrum in a rat model of depression. This will be published on December 7, 2008 in the World Journal of Gastroenterology.

A Sprague-Dawley rat model of chronic stress-induced depression was established. Fifty experimental rats were randomly divided into the five groups: normal control group, fluoxetine + normal control group, depressed model group, saline + depressed model group, and fluoxetine + depressed model group. Laser scanning confocal microscopy (LSCM) immunofluorecence and RT-PCR techniques were used to investigate rMCP-1 expression in gastric antrum. Mast cell morphology was observed under transmission electron microscopy.

They found that depression induced mast cell proliferation, activation, and granule hyperplasia. Compared with the normal control group, the average immunofluorescence intensity of gastric antrum rMCP-1 significantly increased in depressed model group (37.4 7.7 vs 24.5 5.6, P < 0.01) or saline + depressed model group (39.9 5.0 vs 24.5 5.6, P < 0.01), while there was no significant difference between fluoxetine + normal control group (23.1 3.4) or fluoxetine + depressed model group (26.1 3.6) and normal control group. The average level of rMCP-1mRNA of gastric antrum significantly increased in depressed model group (0.759 0.357 vs 0.476 0.029, P < 0.01) or saline + depressed model group (0.781 0.451 vs 0.476 0.029, P < 0.01 ), while no significant difference was found between fluoxetine + normal control group(0.460 0.027) or fluoxetine + depressed model group (0.488 0.030) and normal control group. Fluoxetine showed partial inhibitive effects on mast cell ultrastructural alterations and de-regulated rMCP-1 expression in gastric antrum of the depressed rat model.

These findings will conduce to understand that chronic heterotypic stress may induce the immune responses in gastric mucosa. Treatment with fluoxetine can ameliorate pathological changes in gastric antrum of depressed rat model, suggesting that SSRIs are an effective therapeutic agent for some gastroduodenal diseases caused by psychological factors.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. New study shows that a cough medicine ingredient could effectively treat prostate cancer
2. Common treatment for mens pelvic pain proves ineffective, Queens-led study shows
3. Experts Say Blood Sugar Guidelines Remain Effective
4. Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
5. The Obama Effect: New Job Trends to Watch in 2009
6. MRI scans can predict effects of MS flare-ups on optic nerve
7. The profound effects of numbing agents
8. Precision Optics Corporation to Effect Reverse Split and Ticker Symbol Change
9. Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements
10. New Resource for No Side Effect Drugs
11. New therapy prevents dangerous side effect for lymphoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... A new ... Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an important ... to the report, a wider scope of physical therapy options is showing promising ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... solutions, announced recently the availability of a new professional fee E/M leveling calculator ... their service to the healthcare industry. E/M coding is complex which supports the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... the Founder and Managing Member for t4 Leadership Development & Consulting. He has ... his definition of “success”: physician leadership development, servant leadership, data driven process improvement, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Mostyn Law and Gulf Coast Regional Blood Center to host ... Mostyn Law family has had 3 members that needed ... Mostyn Law is partnering with Gulf Coast Regional Blood Center ... Blood supplies are running low. Gulf Coast Regional Blood Center,s ... August. That is why the blood center reached out to ...
(Date:8/15/2017)... Calif. , Aug. 15, 2017  AOTI Inc. announced today ... Oxygen Therapy Inc., has recently opened a New York City Office ... ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ) ... by the Accreditation Commission for Health Care (ACHC) under the company,s ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
Breaking Medicine Technology: